Get the Stockscreener App
38.39
1.05%
-0.4876
Biohaven Ltd stock is traded at $38.39, with a volume of 273.80K.
It is down -1.05% in the last 24 hours and down -2.63% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
See More
Previous Close:
$38.88
Open:
$38.87
24h Volume:
273.80K
Relative Volume:
0.30
Market Cap:
$3.93B
Revenue:
-
Net Income/Loss:
$-804.34M
P/E Ratio:
-4.08
EPS:
-9.41
Net Cash Flow:
$-531.06M
1W Performance:
+0.58%
1M Performance:
-2.63%
6M Performance:
+11.28%
1Y Performance:
-18.60%
1-Day Range:
$38.03
$39.44
1-Week Range:
$36.83
$40.67
52-Week Range:
$26.80
$62.21
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
38.42 | 3.93B | 0 | -804.34M | -531.06M | -9.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.57 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.57 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.51 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.50 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.28 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Jennison Associates LLC Purchases New Shares in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
China Universal Asset Management Co. Ltd. Makes New $575,000 Investment in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
SG Americas Securities LLC Has $336,000 Holdings in Biohaven Ltd. (NYSE:BHVN) - Defense World
Biohaven Ltd.’s Promising Outlook for Troriluzole in Spinocerebellar Ataxia Amidst FDA Decision - TipRanks
Biohaven FY2025 EPS Forecast Decreased by Leerink Partnrs - MarketBeat
(BHVN) Technical Data - Stock Traders Daily
Biohaven Kickback Case Settled For $59M - NewsBreak
Leerink Partnrs Decreases Earnings Estimates for Biohaven - Defense World
Nebraska Joins in Settling Kickback Allegations against Biohaven Pharmaceutical Holding Company Ltd. - Rural Radio Network
Nebraska joins in settling kickback allegations against Biohaven - norfolkneradio.com
Pfizer to pay nearly $60M over kickbacks for migraine drug developed by New Haven-based Biohaven - Hartford Business Journal
Multiple System Atrophy (MSA) Market 2025-2032 Business - openPR
Nebraska joins multi-state settlement against Biohaven Pharmaceutical for kickback allegations - NEWS CHANNEL NEBRASKA
Nebraska joins in settling kickback allegations against Biohaven Pharmaceutical Holding Company Ltd. - News Channel Nebraska
Pfizer agrees to pay nearly $60M to settle FCA allegations - MSN
Pfizer settles Biohaven kickback claims case for $59.7m - Yahoo Finance
Financial Crime Weekly: Pfizer Pays Nearly $60 Million To Resolve False Claims Allegations, SEC Creates Crypto Task Force - Benzinga
Pfizer settles Biohaven kickback case with DOJ for $60M - MSN
Pfizer settles Biohaven kickback case with DOJ for $60M (PFE:NYSE) - Seeking Alpha
When (BHVN) Moves Investors should Listen - Stock Traders Daily
Cantor Fitzgerald Forecasts Biohaven FY2025 Earnings - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Stock Holdings Raised by ARS Investment Partners LLC - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Insider Stock Buying Reaches US$23.8m On Biohaven - Simply Wall St
Biohaven’s stock surges as treatment slows progress of neurological disorder - MSN
Biohaven (NYSE:BHVN) Trading Down 6.4%Here's What Happened - MarketBeat
Biohaven Refines Epilepsy Trial Design With Patient-Centric Focus - Clinical Leader
Motor Neuron Disease Clinical and Non-Clinical Studies, Key - openPR
Deal Watch: Bausch Companies Set Hectic Pace At J.P. Morgan With Five Deals - News & Insights
Biohaven (NYSE:BHVN) Stock Price Down 6.4%Should You Sell? - MarketBeat
Why Biohaven Ltd. Stocks Are Rising Now - TipRanks
What's Going On With Merus Stock Monday?Biohaven (NYSE:BHVN), Merus (NASDAQ:MRUS) - Benzinga
Biohaven & Merus Team Up to Develop Novel Bispecific ADC Therapies - Contract Pharma
Biohaven Showcases TRAP Degraders at J.P. Morgan Conference - TipRanks
Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generatio - PR Newswire
Merus and Biohaven Partner to Develop Next-Generation Cancer-Fighting ADC Therapies - StockTitan
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs - The Manila Times
Biohaven (NYSE:BHVN) Shares Gap DownHere's What Happened - MarketBeat
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):